Medicus Pharma Ltd. (MDCX), a biotech/life sciences company, announced on Monday that its CEO had conducted a series of meetings with U.S. lawmakers, seeking support for the company's SkinJect product in treating Gorlin Syndrome.
Gorlin Syndrome, or nevoid basal cell carcinoma, is a rare, inherited disorder caused by mutations in the PTCH1 gene, dysregulating the Hedgehog pathway. This leads to early, recurrent tumor formations of over 1000 basal cell carcinomas, often beginning in childhood. The disease currently has no therapies approved by the U.S. Food and Drug Administration (FDA).
Medicus developed SkinJect as an immuno-oncological precision product for localized, repeat, non-surgical treatments of non-melanoma skin diseases.
The company's Chief Executive Officer, Raza Bokhari, engaged with lawmakers to discuss orphan drug designation for SkinJect, a registrational investigational new drug (IND) approval for Gorlin syndrome, in addition to a rare disease pediatric FDA voucher program.
Medicus previously announced a strategic collaboration with the Gorlin syndrome alliance (GSA) to advance access to SkinJect for the treatment of basal cell carcinomas.
MDCX is currently trading at $0.27, down 11.46%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.